CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Capecitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00585078
NCT00585078Phase 2Completed
CompareCT.gov

Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma

Beth Israel Deaconess Medical Center·interventional·Posted Jan 3, 2008·Updated Apr 10, 2017

In Brief

A Phase 2 clinical trial evaluating Capecitabine and Oxaliplatin for Pancreatic Cancer. Completed, enrolled 40 participants across 1 site.

Detailed Summary

There are limited treatment options available for patients with advanced pancreatic ductal adenocarcinoma (PDAC). The purpose of this study is to determine the effectiveness and safety of the drugs capecitabine and oxaliplatin in patients who have been diagnosed with advanced and metastatic PDAC treated in the first and second lines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsSanofi

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 3, 2008
Enrollment StartMay 1, 2004
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 18.5 years ago

Interventions

Capecitabinedrug

Oxaliplatindrug